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Abstract
Introduction: Promising preclinical results have been obtained with blood purification therapies as adjuvant treatment
for sepsis. However, the mechanisms by which these therapies exert beneficial effects remain unclear. Some
investigators have suggested that removal of activated leukocytes from the circulation might help ameliorate remote
organ injury. We designed an extracorporeal hemoadsorption device capable of capturing both cytokines and
leukocytes in order to test the hypothesis that leukocyte capture would alter circulating cytokine profiles and influence
immunological cell-cell interactions in whole blood taken from patients with sepsis.
Methods: We performed a series of ex vivo studies in 21 patients with septic shock and 12 healthy volunteers. Blood
circulated for four hours in closed loops with four specially designed miniaturized extracorporeal blood purification
devices including two different hemoadsorption devices and a hemofilter in order to characterize leukocyte capture
and to assess the effects of leukocyte removal on inflammation and immune function.
Results: Hemoadsorption was selective for removal of activated neutrophils and monocytes. Capture of these cells led
to local release of certain cytokines, especially IL-8, and resulted in complex cell-cell interactions involved in cell-
mediated immunity. Inhibition of cell adherence reversed the cytokine release and the effects on lymphocyte function.
Conclusions: Monocyte and neutrophil capture using a sorbent polymer results in upregulation of IL-8 and
modulation of cell-mediated immunity. Further studies are needed to understand better these cellular interactions
in order to help design better blood purification therapies.
Introduction
Sepsis is the most common cause of death in the intensive
care unit [1]. Care is mostly supportive as specific treat-
ments for sepsis have failed to become universally accepted
[2-5]. Blood purification techniques, including high-volume
hemofiltration (HVHF), cascade hemofiltration, hemoad-
sorption, plasmapheresis, coupled plasma filtration adsorp-
tion (CPFA), high-adsorption hemofiltration, and high
cut-off hemodialysis/hemofiltration, represent a class of
therapies for sepsis that have seen promising pre-clinical
and early clinical results but have not yet been translated
into routine clinical practice [6-12].
There are several explanations for the lack of transla-
tion of experimental findings from blood purification
studies into clinical practice. First, there are no large
multicenter trials evaluating the ability of blood purifica-
tion therapies to improve patient-centered outcomes in
sepsis. Second, the non-specific nature of these therapies
in removing inflammatory mediators has raised the con-
cern that small beneficial molecules (for example, anti-
biotics, nutrients, vitamins, trace elements) may also be
removed [13-15]. Third, the mechanisms by which these
therapies exert beneficial effects remain poorly under-
stood and controversial [16].
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Recent evidence suggests that these therapies may not
only remove soluble mediators of inflammation but may
also work at the cellular level, modulating immune func-
tion by interacting directly or indirectly with inflamma-
tory cells [12,17-20]. Furthermore, adsorptive materials
such as polymyxin B not only adsorb inflammatory med-
iators and toxins but also remove leukocytes due to cell
adsorption onto the surface of the blood purification
device [21-24]. Some investigators have suggested that
removal of activated leukocytes from the circulation
could ameliorate remote organ injury [22,23,25]. Apher-
esis systems have even been developed with the purpose
of leukocyte capture in the setting of acute kidney injury,
chronic kidney disease and other refractory inflammatory
diseases (for example, ulcerative colitis) [25-29].
As part of an ongoing project to develop a blood purifi-
cation device for the treatment of sepsis, we designed an
extracorporeal hemoadsorption device capable of captur-
ing not only cytokines but also leukocytes. We hypothe-
sized that leukocyte capture would alter the immune
response to sepsis. To address this, we performed a series
of ex vivo studies with the aim of characterizing leukocyte
capture using different extracorporeal blood purification
devices. Two different hemoadsorption devices using sor-
bent polymer were tested, along with a hemofilter used as
a control, and the effects of these interactions on inflam-
mation and immune function were characterized in the
setting of human sepsis.
Materials and methods
Overview
We obtained blood from both patients with septic shock
and healthy volunteers and circulated it for four hours in a
closed loop with one of four specially designed miniatur-
ized extracorporeal devices. At baseline and at the end of
the session, we measured white blood cell and differential
counts, plasma concentrations of various inflammatory
mediators, leukocyte cell surface molecule expression and
lymphocyte function.
Subjects
The study was approved by the University of Pittsburgh
Institutional Review Board. After consent was obtained,
blood was withdrawn from 21 patients with septic shock
and from 12 healthy volunteers. Septic shock was
defined according to the American College of Chest
Physicians/Society of Critical Care Medicine consensus
conference criteria [30]. Patients were excluded if preg-
nant, younger than 18 years, receiving renal replacement
therapy, receiving immunosuppressive therapy or if they
had a history of hematological malignancy. Healthy
volunteers were older than 18 years of age and not
pregnant.
Ex vivo circuits and blood purification devices
Blood was collected into standard vacuum-collection
tubes. The experiments consisted of perfusing blood
through four different closed miniaturized ex vivo extra-
corporeal circuits over a period of four hours: 1) a
hemoadsorption device containing 1.5 g of large
(approximately 550 to 600 μm diameter) polystyrene
divinylbenzene copolymer beads (Cytosorb™; CytoSor-
bents Corporation, Monmouth Junction, NJ, USA); 2) a
hemoadsorption circuit containing 2.5 g of small (70 to
75 μm diameter) Cytosorb beads; 3) a hemofiltration cir-
cuit with a mini hemofiltration device (Oxiris®, Gam-
bro-Hospal, Meyzieu, France); and 4) a sham circuit
consisting of the extracorporeal circuit with no blood
purification device (that is, a tubing circuit with just an
empty cartridge) (Figure 1).
Components of the extracorporeal circuits were poly-
ethylene tubing, a 15 ml blood reservoir (Origen™, Aus-
tin, TX, USA), silicone tubing and a peristaltic pump
(Control Company, Friendswood, TX, USA) set up with
a blood flow rate of 0.75 ml/minute. For the hemofiltra-
tion circuit, saline was used for replacement fluid. The
ultrafiltration flow rate and the replacement fluid flow
rate were both 0.15 ml/minute, maintaining the total
blood volume consistently stable at 15 ml. This polyacri-
lonitrile mini-hemofilter had a surface area of 420 cm2
and was specifically designed and miniaturized for this
study. The surface polarity of this blood purification
membrane was modified by the addition of a polyethyle-
neimine coating, a positively-charged polymer, allowing
the membrane to catch negatively charged endotoxins
via surface adsorption. For the hemoadsorption circuits,
the beads were located inside miniaturized cartridges.
The difference in diameter between large and small
beads resulted in a significant increase of the contact
area with blood, from 45 cm2 (large beads) to 297 cm2
(small beads). In all circuits, unfractionated heparin was
added to the blood before the beginning of each experi-
ment in order to obtain a heparin concentration of
10 IU/ml. Information regarding the miniaturized hemo-
filtration and hemoadsorption devices is summarized in
Table 1.
Electron microscopy and immunofluorescence images
We studied the cell adherence to the hemoadsorption
beads using scanning electron microscopy (SEM) and
characterized adherent cells using immunofluorescence
(IF) microscopy.
SEM
Following the experimental period, beads were removed
from the cartridges and fixed in 1% OsO4. Specimens
dehydrated in alcohol gradients were then imaged using
JEOL 9335 SEM.
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Figure 1 The four ex vivo miniaturized extracorporeal circuits (hemofiltration, hemadsorption with large beads, hemoadsorption with
small beads and sham). Blood was circulated through these closed circuits for four hours. HA-LB, hemoadsorption with large beads; HA-SB,
hemoadsorption with small beads; HF, hemofiltration; P, mini-pump; RF, replacement fluid; UF, ultrafiltrate.
Table 1 Summary of the characteristics of the miniaturized blood purification devices
Large bead hemoadsorption
device (HA-LB)
Small bead hemoadsorption
device (HA-SB)
Hemofiltration
device (HF)
Material Polystyrene divinyl benzene
copolymer
Polystyrene divinyl benzene
copolymer
Polyacrilonitrile
Average bead diameter (µm) 535 72.5 n/a
Total outer surface area = contact with blood
(m2)
0.0045 0.0297 0.0420
Total inner porous surface area = contact with
plasma (m2)
1,275 2,125 Information not
provided
Pore size (nm) < 5 < 5 2.9
Blood flow rate (ml/min) 0.75 0.75 0.75
Ultrafiltrate flow rate (ml/min) 0.15
Replacement fluid flow rate (ml/min) 0.15
Length of the hemofilter fibers (cm) n/a 21
Hemofilter filter wall thickness (µm) 50
Number of fibers per hemofilter 264
Hemofilter fiber internal diameter (µm) 240
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IF
The beads were fixed in 2% paraformaldehyde, blocked
with 2% bovine serum albumin (BSA) and then incu-
bated with CD14 (Abcam, Cambridge, MA, USA) pri-
mary antibody. Fluor-conjugated phalloidin for F-actin
and nuclear stain 4’,6-diamidino-2-phenylindole (DAPI)
were also co-incubated. Beads were then imaged using
an Olympus Fluoview confocal microscope.
Cytokine measurements
Blood samples were withdrawn from the circuits at
baseline and after four hours of circulation. Samples
were immediately centrifuged at 1,500 × g for 5 minutes
at 4°C and plasma was removed and stored at -80°C
until assayed. Granulocyte macrophage colony-stimulat-
ing factor (GM-CSF), tumor necrosis factor (TNF),
interferon g and the interleukin (IL) -1 b, IL-2, IL-4, IL-
5, IL-6, IL-8, and IL-10 concentrations were measured
in duplicate by Luminex® bead technology (Invitrogen,
Camarillo, CA, USA).
Leukocyte surface marker expression
Cell surface markers were measured in monocytes, neu-
trophils and lymphocytes. Blood samples were withdrawn
at baseline and after four hours of circulation through the
circuits. Erythrocytes were lysed with BD Pharm Lyse™
solution (Becton Dickinson, Franklin Lakes, NJ, USA) and
washed in 1% BSA in PBS. Fc receptors were blocked with
excess immunoglobulin G (IgG). Cells stained for surface
markers were incubated with appropriate antibodies
(Becton Dickinson) and fixed in 1% paraformaldehyde. For
nuclear factor kappa B (NFB), cells were treated with
Cycletest Plus Kit (Becton Dickinson) prior to staining
with anti-NFB antibody (Santa Cruz Biotechnology Inc,
Santa Cruz, CA, USA). Data were acquired on a Beckman
Coulter XL-MCL and analyzed with FCS Express (De
Novo Software, Los Angeles, CA, USA). Cells were gated
by size and granularity for neutrophils and monocytes.
NFB cells were gated for positive staining of propidium
iodide (PI) and by size. HLA-DR, CD 11b, CD 11a, CD
62L, TNF-alpha converting enzyme (TACE), and NFB
expression was measured by the geometric mean of fluor-
escence intensity. Apoptosis was measured as percent
positive for Annexin V with PI excluding necrotic cells.
T-cells were stained with BD Fast-Immune mix of CD3/
CD4/CD69. T-Lymphocytes were gated on CD3+ and
gated into CD4+ and CD4- populations. CD69 was mea-
sured as % positive and as geometric mean of CD3+/CD4
+ and CD3+/CD4- cells.
Measurement of lymphocyte function
We measured intracellular ATP production in CD3+
and CD4+ lymphocytes as a marker of global lympho-
cyte immune function following phytohemagglutinin
(PHA) and concavalin (Con-A) mitogen stimulation
(The Cylex’s Immuknow® & T-Cell Memory™ assays,
Cylex Inc., Columbia, MD, USA). Briefly, for both
assays, 250 μl of whole blood was diluted with sample
diluent, then added to the appropriate wells of the
microtiter plates and incubated for 15 to 18 hours at
37°C, with and without stimulant (PHA or Con-A). The
following day, CD4+ or CD3+ cells were selected within
the microwells using magnetic particles coated with
anti-human CD4 and CD3 monoclonal antibodies
(Dynabeads®, Dynal Biotech ASA, Oslo, Norway),
washed to remove residual cells and lysed with lysis
reagent to release intracellular ATP. ATP was measured
using a luciferase-based reaction with a luminometer.
Results were expressed as the amount of ATP in nano-
grams per milliliter of whole blood.
Experiments with ethylenediaminetetraacetic acid
Blood was withdrawn from seven healthy volunteers and
was circulated through the four circuits during four hours.
Blood collection tubes containing ethylenediaminetetraa-
cetic acid (EDTA) were used and no additional anticoagu-
lation was added in the circuits after blood draw, leading
to an EDTA concentration of 1.8 mg per milliliter of
blood. White blood cell and differential counts, cytokine
level measurements and lymphocyte function activity were
recorded.
Statistical analysis
Non-normally distributed continuous data were
expressed as the median and interquartile range (IQR).
Where indicated, values were normalized to conditions
before exposure to the indicated devices and are reported
as % Uncirculated. Comparison of group differences for
continuous variables was done by the non parametric
Mann-Whitney test. Statistical tests were performed
using the Sham group as the reference. A statistical and
graphing software program (GraphPad Prism, version 5,
GraphPad Software, La Jolla, CA) was used for data pro-
cessing and analysis. All P values were two-sided and sta-
tistical significance was set at an a-value of 0.05.
Results
Hemoadsorption devices were selective for removal of
neutophils and monocytes
Blood circulation through all four circuits resulted in the
removal of leukocytes and platelets, both from septic
and healthy blood (Figure 2). This was particularly sig-
nificant for hemoadsorption, especially with the small
beads, where less than 10% of platelets and leukocytes
remained circulating at the end of the experiments with
septic blood. Importantly, the leukocyte depletion was
primarily seen in monocytes and neutrophils whereas
lymphocytes showed little affect. The circuit without a
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blood purification device (sham circuit) was responsible
for a slight decrease in leukocytes and platelets. EM and
IF images confirmed adsorption of leukocytes and plate-
lets onto the surface of the beads (Figure 3).
Hemoadsorption resulted in depletion of CD11b positive
cells and led to release of IL-8 and TNF
Compared to baseline, hemofiltration and hemoadsorp-
tion decreased the concentration of IL-6 and IL-10 in
septic blood (Figure 4). As expected, cytokine levels in
healthy volunteers were very low. A significant produc-
tion of IL-8 and TNF occurred with the large bead
hemoadsorption device; levels increased in both septic
and healthy blood. Although changes in TNF were sta-
tistically significant, levels were quite low, especially in
septic blood (< 10 pg/ml). However, IL-8 levels increased
dramatically, exceeding 1,000 pg/ml in both septic and
healthy blood. IFN-g, IL-2, IL-4 and IL-5 levels did not
change after circulation through the devices. Neutrophils
and monocytes remaining in circulation at the end of the
Figure 2 Effects of extracorporeal circuits on white blood cells (WBC), neutrophils (PMN), monocytes (Mono), lymphocytes (Lymph)
and platelets (Plts). Results are expressed as % of cells present before circulation through the circuits (uncirculated condition), in blood
obtained from septic patients and healthy volunteers (medians with interquartile ranges). *P < .05, **P < .01, ***P < .001 compared with Sham.
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experiment with hemoadsorption were less likely to
express CD11b (Figure 5). By contrast, molecules
expressed on the surface of lymphocytes were not chan-
ged after blood purification using the different devices.
Monocyte depletion leads to modulation of lymphocyte
function
Although lymphocytes were not captured by the devices,
T cell activity (both CD3+ and CD4+) was decreased
with hemoadsorption, both in septic and healthy blood
(Figure 6). In septic blood, the Immuknow value with
PHA stimulation decreased from 361 (53 to 462) to 72
(3 to 219), P = 0.0464 (large beads), and to 9 (2 to 13),
P = 0.0048 (small beads). Similar results were seen with
Con A stimulation: 154 (17 to 394) to 40 (15 to 69), P =
0.0071 (large beads) and to 1 (0.3 to 3) P = 0.0007
(small beads). By contrast, there was no significant
change of the Immuknow value when blood was circu-
lated through the sham and the hemofiltration circuits.
EDTA blocked cell capture, ameliorated IL-8 release and
reversed T-cell suppression
In order to determine if the effects on cytokines and
T-cells were mediated by capture of neutrophils and/or
monocytes, we circulated healthy blood through the cir-
cuits after anticoagulation with increased concentrations
of heparin, citrate and EDTA. In these experiments,
there was no change with heparin and citrate (data not
Figure 3 Electron microscopy (EM) and immunofluorescence (IF) images showing cell adsorption onto the beads.
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shown). However, EDTA blocked leukocyte and platelet
capture (Figure 7) leading to markedly attenuated IL-8
release (reaching only 67 pg/ml with the large bead
device). Immuknow values remained similar with
hemoadsorption as compared to the baseline value. Of
note, the Immuknow is affected by EDTA since the
PHA results before circulation through the circuits are
already reduced (see comparison with Figure 6). Con A
is suppressed completely and cannot be evaluated (data
not shown).
Discussion
In this ex vivo study using human whole blood taken from
patients with sepsis and healthy volunteers, we tested the
hypothesis that leukocyte capture modulates inflammatory
cytokines and immune cell function. We designed a new
hemoadsorption device, capable of capturing not only
inflammatory mediators but also activated leukocytes, and
we examined the effects of this therapy on inflammation
and immune function. Our results showed that while
monocytes and neutrophils (along with platelets) were
captured by the hemoadsorption device, lymphocytes were
not affected. Furthermore, capture was preferential to acti-
vated cells as evidenced by the marked reduction in
CD11b+ and less dramatic reduction in CD11a+ cells
remaining in circulation after treatment. Importantly, cap-
ture of monocytes and neutrophils led to local release of
certain cytokines, especially IL-8, and resulted in changes
in T-cell function as measured by response to stimulation
with PHA and Con A. Inhibition of monocyte and
Figure 4 Effects of extracorporeal circuits on cytokine concentrations, in septic and healthy blood. Data are expressed as % of the
uncirculated condition (medians with interquartile ranges). GM-CSF, granulocyte macrophage colony stimulating factor; IFN, interferon; IL,
interleukin; TNF, tumor necrosis factor. *P < .05, **P < .01, ***P < .001 compared with Sham.
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neutrophil capture with EDTA nearly abolished IL-8
release and reversed the T cell suppression.
Numerous experimental and clinical studies have
reported that various forms of extracorporeal blood purifi-
cation used in sepsis are effective in clearing inflammatory
mediators and endotoxins from the plasma and are
responsible for an improvement of physiological para-
meters (for example, hemodynamics, oxygenation)
[7,8,10,17,31]. Cruz et al. recently showed reduced mortal-
ity when hemoadsorption was used in patients with
abdominal sepsis [2]. However, the mechanisms by which
these therapies exert beneficial effects are not entirely
understood [16]. Recent evidence suggests that these
blood purification therapies may not only remove soluble
mediators of inflammation but may also work at the cellu-
lar level, modulating the immune function by interacting
directly or indirectly with inflammatory cells [12,17-20].
Moreover, it has recently been shown that polymyxin B
hemoadsorption does more than adsorb inflammatory
mediators and toxins– it also removes leukocytes via cell
adsorption onto the surface of the device [21-23]. Kumagai
et al. found very similar results to ours with a significant
decrease of neutrophils, monocytes and lymphocytes after
ex vivo polymyxin B hemoadsorption (78%, 70% and 10%,
respectively, compared with baseline values). Additionally,
this study also suggested that the adhesion of leukocytes
preferentially affected activated neutrophils, therefore
resulting in a decreased ability for the remaining circulat-
ing cells to cause endothelial damage [22]. Similarly, Abe
et al. also demonstrated that a large number of cells cap-
tured by polymyxin B-immobilized fiber columns were
activated neutrophils, highly expressing HLA-DR, CD14,
Figure 5 Effects of extracorporeal circuits on leukocyte surface marker expression, in septic blood. (A, B) Geometric mean of
fluorescence intensity of CD 11b, HLA-DR, CD 11a, CD 62L, TACE, and NFkB and positive cells for Annexin V in monocytes and PMN. Data are
expressed as % of the uncirculated condition (medians with interquartile ranges). (C) Percentage of CD3+/CD4- and CD3+/CD4+ cells among
T-lymphocytes (medians with interquartile ranges). (D) Percentage of positive cells for CD69 among CD3+/CD4- and CD3+/CD4+ cells (medians
with interquartile ranges). (E): Geometric mean of fluorescence intensity of CD69 in CD3+/CD4- and CD3+/CD4+ cells (medians with interquartile
ranges). *P < .05, **P < .01, ***P < .001 compared with Sham. Annex. V, Annexin V; Mono, monocytes; NFkB, nuclear factor-kappa B; PMN,
neutrophils; TACE, tumor necrosis factor-alpha converting enzyme.
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CD62L and CD114 [21]. Finally, another recent report
from Nishibori et al. also suggested that a polymyxin B-
immobilized fiber column specifically removed monocytes
that had been activated during septic shock [23].
In our study, when blood was exposed to the hemoad-
sorption device, we observed that circulating platelet,
monocyte and neutrophil counts decreased due to their
adsorption onto the beads (Figures 2 and 3). Leukocyte
Figure 6 Effects of extracorporeal circuits on Immuknow & T-Cell Memory assays in septic and healthy blood. Data are expressed as
absolute values of the amount of ATP in nanograms per milliliter of whole blood (medians with interquartile ranges). *P < .05, **P < .01, ***P <
.001 compared with Sham. Con-A, concavalin A; PHA, phytohemagglutinin.
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and platelet counts were both significantly reduced with
hemoadsorption compared to sham and were even more
reduced with the small beads, as compared to the large
beads, most likely due to the increased surface area and
reduced interstitial space between beads in the device.
Moreover, it seems likely that adsorption of platelets, neu-
trophils and monocytes occurred in an inter-related way
[32,33]. Indeed, it is known that platelets are readily acti-
vated by shear force and contact with biomaterials [34].
This activation, in turn, leads to changes in the surface
expression of integrins and adhesion molecules, leading to
platelet aggregation and deposition on biomaterials. Plate-
let activation also leads to release of cytokines, thereby
providing both the chemical signal and appropriate surface
for leukocyte activation and adhesion [35,36].
Importantly, we also found that captured leukocytes
released low levels of TNF and very high levels of IL-8.
IL-8, a chemokine, is mainly produced by activated mono-
cytes and functions to recruit neutrophils (IL-8 is also
known as neutrophil chemotactic factor) [37]. Interest-
ingly, our devices did not capture lymphocytes. Lympho-
cyte concentrations remained quite stable after circulation
through the circuits and this correlates with the absence
of production of the lymphokines IL-2, IL-4, IL-5 and
IFNg (Figure 4) and the absence of changes in the expres-
sion of CD4, CD8 and CD69 on the lymphocyte surface
(Figure 5).
We evaluated T-lymphocyte function with the Immu-
know test. This assay is approved for monitoring immune
cell function in immunosuppressed populations [38].
Immune cell function is considered low when values
of this assay are below 225 ng/ml, medium when 225 to
525 ng/ml and high (normal) when more than 525 ng/ml
[39]. T-cell function was much more affected with small
Figure 7 Experiments with EDTA. Effects of extracorporeal circuits on WBC count (A), cytokine concentrations (D, E, F) and Immuknow & T-
Cell Memory assays (B), in healthy blood, when circuit anticoagulation was performed with EDTA instead of heparin. Plots show the medians
with interquartile ranges. An immunofluorescence picture of a large bead after blood circulation is also shown (C). *P < .05, **P < .01, ***P <
.001 compared with Sham. EDTA, ethylenediaminetetraacetic acid; WBC, white blood cell.
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bead hemoadsorption rather than with large beads. Indeed,
after four hours of circulation in the small bead circuits,
lymphocytes were unresponsive (Figure 6). Furthermore,
our findings support the conclusion that lymphocyte func-
tion was not altered because of a decrease in the number
of lymphocytes or lymphocyte subtypes (Figures 2 and 5).
Since the activation of T cells needs to occur in the
presence of antigen presenting cells, the removal of mono-
cytes that function as antigen presenting cells in this
in vitro system most likely explains the absence of
response from the T-cells. This was confirmed by the
EDTA experiments that abolished cell capture and com-
pletely reversed the inhibition of lymphocyte activation.
Our study has some limitations. First, as an ex vivo
investigation, we cannot determine the clinical effects of
the changes in cell numbers and function we observed.
Our closed loop experimental design using fresh whole
blood ex vivo is not comparable to that seen in vivo.
Indeed, ex vivo circuits work as a single compartment
model, whereas the in vivo use of a hemoadsorption car-
tridge integrates into a multi-compartment state where
activated cells move into tissues or adhere to vessel walls
and are then not available for capture by the device. More-
over, as compared to the total blood volume of the ex vivo
circuit, the surface area of the hemofiltration membrane
was proportionally larger than what it could be in a
human in vivo condition. The effects of the devices could,
therefore, have been magnified. Second, our results on leu-
kocyte surface marker expression reflect only the remain-
ing circulating cells not those adsorbed onto the beads.
Indeed, we could not study the adherent cells directly and
can, therefore, only infer what their surface marker expres-
sion profile was like. Moreover, we are unable to answer
the question whether or not the cell adsorption was a
transient or a definitive phenomenon. Third, the relatively
low Immuknow absolute values observed in all groups
during the EDTA experiments (particularly with Con A),
as compared with heparin or citrate anticoagulation, may
most likely be explained by the metal ion chelating proper-
ties of EDTA, affecting peripheral blood mononuclear cell
proliferation and stimulation [40]. Indeed, we were sur-
prised to observe no change in cell capture with heparin
or citrate despite some evidence that these agents have dif-
fering effects when used for anticoagulation of extracor-
poreal devices in models of sepsis [41].
These limitations aside, this study supports the novel
concept that capture of activated leukocytes from the cir-
culation can be achieved by hemoadsorption. Such ther-
apy could be beneficial by removing activated cells that
have deleterious effects, such as disruption of endothelial
integrity and impairment of microcirculation by overpro-
duction of proteases and oxygen radicals [22,42-44]. This
approach is already used as a therapeutic strategy for
other inflammatory diseases. Indeed, some extracorporeal
apheresis systems (for example, cellulose acetate beads)
have been developed to remove activated monocytes and
granulocytes in order to treat specific refractory and
inflammatory diseases associated with leukocytes such as
ulcerative colitis, neutrophilic dermatosis and psoriatic
arthritis [27-29]. More recently, Humes et al. have also
developed a selective cytopheretic inhibitory synthetic
membrane to treat the immunological dysregulation of
acute kidney injury and chronic kidney disease, binding
and inhibiting circulating activated leukocytes along a
continuous renal replacement extracorporeal circuit
[26,45].
Conclusions
In summary, our study shows that capture of activated
monocytes and neutrophils by hemoadsorption inter-
feres with the immune response, modulating T-cell
function. These findings lead us to propose a new
mechanism for how blood purification therapies may
modulate the immune response in patients with sepsis.
Additional studies are needed to further investigate this
concept.
Key messages
• Leukocyte capture using a hemoadsorption device
modulates cell-mediated immunity.
• Removal of activated leukocytes may offer great
potential as an adjunct treatment for sepsis and may
help explain some of the beneficial effects of existing
blood purification therapies.
• Further knowledge of the complex cell-cell interac-
tions that occur inside a leukocyte capture device is
needed in order to develop this technology.
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